Respiratory syncytial virus infectious disease

Researchers are testing a single injection vaccine designed to protect adults 60 and older from two respiratory viruses: RSV and HMPV. The trial plans to enroll about 8,000 participants who will randomly receive either the vaccine or a placebo. Scientists will track who develops …

This trial is testing a new vaccine called rBCG-N-RSV, which is based on the BCG vaccine (used for tuberculosis) but modified to also target respiratory syncytial virus (RSV). The study involves 200 adults over 60 years old, who will receive either this new vaccine or the standar…

This early-stage trial tests an experimental mRNA vaccine called YKYY025 designed to protect against respiratory syncytial virus (RSV). Healthy adults aged 18 and older receive a single injection of either the vaccine or a placebo. Researchers monitor safety, side effects, and im…

This phase 3 trial is investigating whether giving a repeat dose of the RSVpreF vaccine to immunocompromised adults is safe and triggers a strong immune response. Participants, aged 18 and older, will receive one shot and be monitored for about a year. The study aims to find the …

This study tests an experimental vaccine from GSK that targets two respiratory viruses: RSV and hMPV. About 1,800 adults aged 18-80 will receive different doses to check safety and immune response. The goal is to see if a single shot can protect against both viruses, which can ca…

This early-stage trial tests an experimental mRNA vaccine called mRNA-1365 in healthy adults aged 60 and older. The vaccine is designed to trigger immunity against two respiratory viruses—RSV and hMPV—which can cause severe illness in older people. Researchers will evaluate the v…

This study tests an experimental vaccine called RSVpreF in adults to see if it is safe and triggers a strong immune response against respiratory syncytial virus (RSV). Around 540 adults in India will receive either the vaccine or a placebo. Researchers will monitor for side effec…

This study tests a new nasal spray vaccine (BLB-201) to prevent RSV, a common virus that can cause serious breathing problems in young children. About 137 infants and children aged 8 to 59 months will receive either the vaccine or a placebo. The goal is to check if the vaccine is…

This trial is testing an experimental vaccine designed to protect against two respiratory viruses at once: RSV and HMPV. The study involves about 2,400 adults aged 60 and older, who will receive one of several dose levels of the vaccine, a placebo, or a control vaccine. Researche…

This study tests an RSV vaccine in adults aged 18-59 who have health conditions like chronic lung, heart, or kidney disease that put them at higher risk for severe RSV. The goal is to see if the vaccine triggers a strong immune response and is safe. Participants receive one shot …

This study tests a new vaccine against respiratory syncytial virus (RSV) in adults. Phase I includes adults 18 and older to check safety of different doses. Phase II focuses on adults 60 and older to see how well the vaccine triggers an immune response and how safe it is. The vac…

This large study tests an RSV vaccine given to pregnant women to see if it safely protects their babies from severe RSV infection in the first months of life. About 13,000 pregnant women in Africa will receive either the vaccine or a placebo. The study also closely monitors wheth…

This early-stage trial is testing several new vaccine formulas against RSV and H5N1 bird flu in 570 healthy adults aged 18 to 49. The main goals are to check safety and see how well the vaccines trigger an immune response. Participants will receive one or two shots and be followe…

This study looks at how well the RSV vaccine Arexvy works in 170 adults with weakened immune systems. Participants will receive up to 3 vaccine doses over a year and be monitored for side effects and immune response. The goal is to find the best dosing schedule to protect this hi…

This Phase 3 trial is testing a new RSV vaccine in 25,000 adults aged 60 and older. The goal is to see if a single shot can prevent lower respiratory tract disease caused by RSV. Participants are randomly assigned to receive either the vaccine or a placebo, and researchers will m…

This study looks at how well the approved RSV vaccine Arexvy works in people aged 80 and older compared to those aged 60-65. Researchers will measure immune responses and side effects. The goal is to see if the vaccine protects the oldest and frailest adults as effectively as you…

This study tests whether giving a second dose of an RSV vaccine to pregnant women who already received it in a prior pregnancy is safe and boosts immunity. About 550 women aged 18-49, between 24-36 weeks pregnant, will receive either the vaccine or a placebo. Researchers will tra…

This study tests an experimental antiviral drug called S-337395 in adults with RSV who are at high risk for severe illness. Participants must have symptoms for less than 72 hours and a confirmed RSV infection. The goal is to see if the drug can lower the amount of virus in the bo…

This study tests whether the antiviral drug remdesivir can help treat RSV (a common respiratory virus) in people whose immune systems are weakened by certain cancer treatments or autoimmune therapies. About 60 adults with confirmed RSV will receive remdesivir intravenously. The m…

This study tests an experimental oral drug called zelicapavir in 150 children aged 1 month to 3 years who have respiratory syncytial virus (RSV). The drug aims to stop the virus from multiplying and speed up recovery. Half the children will get the drug, half a placebo, and resea…

This phase 3 trial tests whether an inhaled solution of human interferon α1b can safely help children under 2 years old recover from respiratory syncytial virus (RSV) lower respiratory tract infections. The study compares the interferon treatment to a placebo, measuring improveme…

This study tests an oral antiviral called ziresovir (AK0529) in adults at high risk for severe RSV infection, such as those with chronic lung or heart disease, weakened immune systems, or age 65 and older. Participants receive either the drug or a placebo, and researchers measure…

This early-stage trial tests a new drug called PRS CK STORM, made from a mix of immune and fat cells, to see if it can safely calm the 'cytokine storm'—a dangerous overreaction of the immune system—in people with severe lung infections from COVID-19, flu, or RSV. The study will e…

This study tests whether the antibiotic azithromycin can help children with severe RSV infection who need breathing support in the ICU. About 370 children will receive either azithromycin or a placebo for three days. The main goal is to see if the drug shortens the time they need…

This study is looking at whether it's safe and effective to give the Tdap vaccine (for whooping cough) and the RSV vaccine at the same doctor's visit during pregnancy, or if they should be given separately. The researchers will recruit 60 healthy pregnant individuals and randomly…

This study tests whether giving both an RSV vaccine to pregnant women and an antibody shot to their babies prevents RSV infection better than giving only the baby shot. About 1000 pregnant women in France will be randomly assigned to one of two groups. The goal is to see if the c…

This study looks at whether giving infants an RSV preventive antibody at the same time as their regular vaccines is safe. About 524 babies aged 6 weeks to under 30 weeks will take part. Researchers will compare fever rates in babies who get the RSV shot together with vaccines ver…

This study tracks the safety of Beyfortus (Nirsevimab) in up to 3,000 Korean children under 24 months who receive the shot to prevent RSV. Researchers will monitor for side effects and serious events over 180 days. It is a real-world safety check, not a test of how well it works.

This early-stage trial is testing an experimental drug called SIBP-A16 in 140 healthy adults aged 18 to 45. The goal is to see if it is safe and how the body handles it. Participants receive a single injection of the drug, a placebo, or an existing RSV antibody. The study does no…

This study tests whether community health worker counseling and text message reminders can increase RSV vaccination among Latino adults aged 50 and older in San Francisco and Daly City. Researchers will also see if younger adults can encourage their older friends and family to ge…

This phase 3 trial tests an oral medicine called deurremidevir in infants and young children (1 month to 3 years old) with RSV infection. The goal is to see if it can shorten the time until symptoms like wheezing and rapid breathing go away. About 498 children will receive either…

This study observes how many eligible infants in Queensland receive the RSV immunisation (nirsevimab) during their first RSV season. Researchers will survey 1,200 parents to understand why they chose for or against the shot, and look at factors like location and health risks. No …

This study reviews medical records from up to 400,000 U.S. Veterans to see how COVID-19 treatments like Paxlovid and remdesivir are used and how well they work. It also looks at RSV and flu patterns. The goal is to improve treatment strategies for respiratory viruses in the VA he…

This study will track 10,000 adults in Hong Kong with respiratory symptoms to measure how often RSV causes illness and how severe it gets. Researchers will collect nose and throat samples and blood tests over several weeks. The goal is to fill knowledge gaps about RSV in adults a…

This study in Lusaka, Zambia, aims to measure how common influenza, RSV, and COVID-19 are among adults with flu-like symptoms, comparing those with and without HIV. Researchers will follow participants for two weeks to track symptom progression and outcomes. They will also test w…

This study will track which respiratory viruses—like flu, COVID-19, and RSV—are circulating in French primary care clinics each winter. Up to 25,000 patients with cold or flu symptoms will provide a saliva or nose swab sample. The goal is to monitor virus activity and help guide …

This study follows 300 infants to understand how catching RSV very early (before 4 months old) versus later (after 6-9 months) affects their immune system and long-term health. Researchers will measure antibody responses and track asthma-like symptoms. The goal is to learn why ea…

This study looks at how serious respiratory infections (like flu, COVID-19, and RSV) affect the ability of adults aged 60 and older to live independently. Researchers will follow 1,600 hospitalized seniors across multiple countries to track changes in daily activities such as bat…

This study looks at how often young children get ear infections from RSV, a common virus. Researchers will track 1900 children under 2 years old to see how many have RSV-related ear infections, with or without bronchiolitis. The goal is to better understand the burden of RSV in t…

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…

This study will track 1,000 adults aged 60 and older who are hospitalized in Vietnam with breathing problems or worsening heart/lung conditions. Researchers want to find out how many of these cases are caused by RSV (respiratory syncytial virus) and which types of the virus are i…

This study aims to understand how common respiratory viruses like COVID-19, flu, and RSV spread in communities. Researchers will track up to 25,000 people of all ages using at-home test kits and symptom surveys. The goal is to better predict outbreaks and improve public health re…